Gilead Sciences Inc
GILD
$139.71
-0.42%
Gilead Sciences Inc is a leading biopharmaceutical company focused on developing and marketing therapies for life-threatening infectious diseases, primarily HIV and viral hepatitis. The company is a major player in the infectious disease space and is strategically expanding its oncology presence through targeted acquisitions in cell therapy and cancer treatments.…
GILD
Gilead Sciences Inc
$139.71
Related headlines
Investment Opinion: Should I buy GILD Today?
Based on a synthesis of the financial data, valuation, analyst sentiment, and strategic direction, Gilead Sciences warrants a Buy rating. The company combines defensive qualities—strong profitability, robust cash flow, and a dividend—with an offensive growth strategy in oncology. The current forward P/E of 14.5 and exceptionally low PEG ratio, based on analyst EPS estimates of $12.67, suggest the market is not fully pricing in the long-term earnings potential from its pipeline expansion. While not without risk, the fundamental strength provides a margin of safety for investors.
Sign up to view all
GILD 12-Month Price Forecast
The analysis leans bullish due to Gilead's solid financial foundation and strategically sound, albeit risky, growth investments. The confidence is medium due to the multi-year horizon required for the oncology pipeline to mature and prove its value.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Gilead Sciences Inc's 12-month outlook, with a consensus price target around $181.62 and implied upside of +30.0% versus the current price.
Average Target
$181.62
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$112 - $182
Analyst target range
Wall Street analysts maintain a generally positive outlook on Gilead Sciences, with recent ratings including multiple Buy, Overweight, and Sector Outperform recommendations from firms such as Needham, Truist Securities, Wells Fargo, UBS, and Citigroup. The consensus estimates project average revenue of approximately $37.7 billion and average EPS of $12.67 for the coming period. The recent acquisition activity, including the $7.8 billion purchase of Arcellx, reflects management's confidence in the growth trajectory of its oncology pipeline.
Bulls vs Bears: GILD Investment Factors
Gilead presents a compelling mix of strong current fundamentals and strategic future growth bets. The bullish case is supported by high profitability, shareholder returns, and an undervalued growth profile. However, risks stem from the execution of its expensive oncology pipeline expansion and the maturity of its core HIV business.
Bullish
- Strong Financial Performance: High profitability with 28.9% net margin and robust free cash flow of $9.46B.
- Strategic Oncology Expansion: Recent $7.8B Arcellx acquisition strengthens long-term pipeline in high-growth CAR-T therapy.
- Attractive Valuation: Forward P/E of 14.5 and PEG of 0.01 suggest significant growth potential is undervalued.
- Solid Dividend & Buyback Capacity: 2.6% dividend yield and strong FCF support shareholder returns.
Bearish
- Pipeline Execution Risk: Oncology growth depends on successful integration of large, expensive acquisitions.
- Moderate Leverage: Debt-to-equity of 1.09 could limit financial flexibility if interest rates rise.
- HIV Portfolio Maturity: Core revenue driver faces long-term pricing pressure and competition.
- Recent Price Pullback: Stock down 6.4% in the past month, showing near-term volatility after a strong run.
GILD Technical Analysis
The stock has demonstrated strong overall performance over the past six months, rising 26.06% from its price of $110.56 on October 2, 2025, to $139.37 on March 31, 2026. This significantly outperformed the broader market, as indicated by a 6-month relative strength of +28.88 against the S&P 500.
In the short term, the stock has experienced volatility, declining 6.43% over the past month but still posting a solid 13.55% gain over the last three months. The recent pullback contrasts with the strong rally from late January to mid-February 2026, where the price surged from around $124 to a peak near $156.
The current price of $139.37 places the stock in the upper half of its 52-week range of $93.37 to $157.29, representing approximately 78% of the distance from the low to the high. The stock shows a low beta of 0.374, indicating less volatility than the overall market.
Beta
0.37
0.37x market volatility
Max Drawdown
-17.5%
Largest decline past year
52-Week Range
$93-$157
Price range past year
Annual Return
+24.9%
Cumulative gain past year
| Period | GILD Return | S&P 500 |
|---|---|---|
| 1m | -5.5% | -3.6% |
| 3m | +14.9% | -4.0% |
| 6m | +24.0% | -2.0% |
| 1y | +24.9% | +16.2% |
| ytd | +14.9% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GILD Fundamental Analysis
Revenue growth has been positive, with Q4 2025 revenue of $7.93 billion representing a 4.7% year-over-year increase from Q4 2024. Profitability metrics are strong, with a trailing net margin of 28.9% and an operating margin of 40.1% as of the latest data. Quarterly net income was $2.18 billion in Q4 2025, showing recovery from a net loss in Q1 2024.
The company maintains solid financial health with a current ratio of 1.68, indicating sufficient short-term liquidity. However, the debt-to-equity ratio of 1.09 suggests moderate leverage. Free cash flow generation is robust at $9.46 billion on a trailing twelve-month basis, providing flexibility for dividends, share repurchases, and strategic acquisitions.
Operational efficiency is evidenced by a strong return on equity of 37.6% and return on assets of 12.5%. The company maintains high gross margins of 86.7%, reflecting its pricing power and efficient cost management in its core therapeutic areas.
Quarterly Revenue
$7.9B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$9.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GILD Overvalued?
Given the company's positive net income, the primary valuation metric is the price-to-earnings ratio. Gilead trades at a trailing P/E of 17.94 and a forward P/E of 14.48 based on estimated earnings. The forward P/E suggests the market anticipates earnings growth, which is supported by analyst estimates for the coming year.
Other valuation metrics include a price-to-sales ratio of 5.19, price-to-book ratio of 6.75, and EV/EBITDA of 15.69. The PEG ratio of 0.01 appears exceptionally low, potentially indicating the market is pricing in significant long-term earnings growth relative to the current P/E multiple. Industry average comparisons are not available in the provided data.
PE
17.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -5x~982x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.7x
Enterprise Value Multiple
Investment Risk Disclosure
Gilead's primary risk is pipeline execution. The company is making large, multi-billion dollar bets in oncology (e.g., Arcellx, Ouro Medicines) to diversify away from its mature HIV franchise. The success of these acquisitions is not guaranteed and will require significant capital and R&D investment over several years before contributing meaningfully to earnings, with the Arcellx deal not expected to boost profits until 2028. Financial risk is moderate, with a debt-to-equity ratio of 1.09, which is manageable given the strong $9.46B annual free cash flow but could become a headwind in a higher-for-longer interest rate environment. Operational risks include potential pricing pressure and competition in its core antiviral markets, which could slow top-line growth. The stock's recent 6.4% monthly decline also highlights market sensitivity to broader biotech sentiment and execution timelines.
FAQ
Key risks include pipeline execution, as the success of recent multi-billion dollar acquisitions (Arcellx, Ouro) is critical for future growth but uncertain. Financial leverage is moderate with a debt-to-equity of 1.09. The core HIV business faces long-term pricing and competitive pressures. The stock also exhibits volatility, as seen in its recent 6.4% monthly decline after a strong rally.
The 12-month outlook has a base case target range of $145-$157, aligning with analyst sentiment and the stock's recent trading near its 52-week high of $157.29. The bull case (~30% probability) sees a move above $157 on positive pipeline news, while the bear case (~15% probability) could see a retracement towards the 52-week low of $93.37 if execution falters or markets weaken.
GILD appears modestly undervalued based on forward earnings potential. Its forward P/E of 14.5 is reasonable for a profitable biopharma, and the extremely low PEG ratio of 0.01 suggests the market is pricing in minimal long-term growth, which contrasts with its strategic investments. However, traditional metrics like Price-to-Book (6.75) are elevated, indicating the market values its intangible assets and pipeline.
Based on the synthesized data, GILD is a good stock to buy for investors seeking a blend of value and growth in healthcare. The company's strong fundamentals, including a 28.9% net margin and $9.46B in annual free cash flow, provide a solid foundation. Its strategic acquisitions in oncology and an attractive forward P/E of 14.5 offer a compelling risk-reward profile for the long term.
GILD is more suitable for a long-term investment horizon. The value of its strategic shift into oncology will take years to fully materialize in financial results. Its low beta (0.37) and dividend make it a stable holding, but short-term traders may be challenged by the volatility associated with clinical trial news and biotech sector sentiment.